Evidence map›Paper›PMID 42290055›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2026

[A Case of EGFR-mutant Lung Adenocarcinoma with Secondary SCLC Transformation and ALK Fusion after Osimertinib Treatment].

Liyan Liao, Xiaohong Li

Abstract readCase ReportsEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Liyan LiaoDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Xiaohong LiDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidermal growth factor receptor (EGFR) gene mutations are the most common driver mutations in non-small cell lung cancer (NSCLC). This article reports a case of a patient with EGFR-sensitive mutant lung adenocarcinoma who developed secondary transformation to small cell lung cancer (SCLC) and anaplastic lymphoma kinase (ALK) gene fusion following first-line Osimertinib therapy. This paper reported a case of concurrent SCLC transformation and ALK fusion occurring after Osimertinib treatment, suggesting that the two can coexist as dual drug resistance mechanisms. Re-biopsy combined with genetic testing is essential for identifying drug resistance mechanisms and guiding individualized therapy.
.

Indexed as

Adenocarcinoma of LungAnaplastic Lymphoma KinaseLung NeoplasmsMutationSmall Cell Lung CarcinomaAcrylamidesAniline CompoundsErbB ReceptorsHumansIndolesPyrimidinesAcrylamidesALK protein, humanAnaplastic Lymphoma KinaseAniline CompoundsErbB ReceptorsIndolesosimertinibPyrimidinesAnaplastic lymphoma kinaseEpidermal growth factor receptorLung neoplasmsOsimertinibSmall cell lung cancer transformation

Identifiers

PMID42290055
PMCPMC13314044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.